# Kisunla™ (donanemab-azbt) PRESCRIBER ORDER FORM

| **Patient Name:** | | | **Date of Birth:** | **Gender:** |
|---|---|---|---|---|
| **Address:** | | | | |
| **Phone:** | **Height:** | ☐ inches ☐ cm | **Weight:** | ☐ lbs ☐ kg |

## Clinical Information

| **Primary Diagnosis Description:** | **ICD-10 Code:** |
|---|---|

**Supporting documentation required for therapy:**

- Baseline brain MRI from within the past year. Subsequent brain MRI reports and written approval by the ordering prescriber must be obtained prior to the 2nd, 3rd, 4th, and 7th infusions.

## Kisunla™ (donanemab-azbt) Prescription

**Kisunla™ (donanemab-azbt) in 0.9% sodium chloride refill as directed x 1 year**

☐ **Standard dosing**

| | |
|---|---|
| **Infusion 1:** | Infuse 350mg IV x1 |
| **Infusion 2:** | Infuse 700mg IV x 1, 4 weeks after Infusion 1 |
| **Infusion 3:** | Infuse 1050 mg IV x1, 4 weeks after Infusion 2 |
| **Infusion 4 and beyond:** | Infuse 1400 mg IV every 4 weeks, beginning 4 weeks after Infusion 3 |

☐ **Other:** ____________________________________________________________

Medication will be infused over approximately 30 minutes.
Using a 50ml 0.9% Sodium Chloride IV bag, flush IV tubing with NS 10 to 20 mL after each infusion.
Check vitals and monitor for signs and symptoms at start, throughout infusion, and after completion.

## Ancillary Orders

**Anaphylaxis Kit**

If this is a 1st dose, would you like Option Care Health to provide an anaphylaxis kit with the 1st dose?

☐ Yes ☐ No

Dosage:

- Epinephrine 0.3mg (>30kg), 0.15mg (15 to 30kg), or 0.01 mg/kg (<15kg) SUBQ or IM x 1; repeat x1 in 5 to 15 min PRN.
- Diphenhydramine 25mg (>30kg) or 1.25 mg/kg (≤ 30 kg) IV or IM; repeat x 1 in 15 min PRN no improvement.
- Normal saline 500mL (>30kg) or 250mL (≤30kg) IV at KVO rate PRN anaphylaxis.

**Medication Orders**

☐ Other: ____________________________________________________________

**IV Flush Orders**

- Peripheral: 0.9% Sodium Chloride 2-3 mL pre-/post-use
- Implanted Port: 0.9% Sodium Chloride 5 to 10 mL pre-/post-use and 10 to 20 mL pre-/post-lab draw. Heparin (100 unit/mL) 3 to 5 mL post-use. For maintenance, heparin (100 unit/mL) 3 to 5 mL every 24 hr if accessed or weekly to monthly if not accessed. If unable to obtain implanted port access, it is acceptable to establish a peripheral IV access and administer peripherally.

**Lab Orders**

☐ No labs ordered at this time.

☐ Other: ____________________________________________________________

Skilled nurse to assess and administer via access device as indicated above. Nurse will provide ongoing support as needed.
Refill above ancillary orders as directed x 1 year.
If patient is seen within a provider led infusion clinic, Option Care Health's infusion reaction management policy, skilled nursing plan of treatment, and IV flush administration will be followed per provider oversight. No individual anaphylaxis kit will be dispensed.

*I certify that the use of the indicated treatment is medically necessary, and I will be supervising the patient's treatment.*

**Prescriber Signature:**____________________________________________ **Date:** ____________________

## Prescriber Information

| **Prescriber Name:** | | **Phone:** | **Fax:** |
|---|---|---|---|
| **Address:** | | **NPI:** | |
| **City, State:** | **Zip:** | **Office Contact:** | |

**Fax completed form, insurance information, and clinical documentation to: 713-983-4647**

**CONFIDENTIAL HEALTH INFORMATION**: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that do not require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. **IMPORTANT WARNING**: This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.

**Not valid for use for patients residing in Arizona, New York, and Wisconsin**



© 2026 All rights reserved.